Generic name: tirofiban hydrochloride
Dosage form: injection, solution
This dosage information does not include all the information needed to use Aggrastat safely and effectively. See full prescribing information for Aggrastat.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Use with Aspirin and Heparin
In the clinical studies, patients received aspirin, unless it was contraindicated, and heparin. AGGRASTAT and heparin can be administered through the same intravenous catheter.
AGGRASTAT is intended for intravenous delivery using sterile equipment and technique. Do not add other drugs or remove solution directly from the bag with a syringe. Do not use plastic containers in series connections; such use can result in air embolism by drawing air from the first container if it is empty of solution. Any unused solution should be discarded.
Directions for Use
AGGRASTAT Injection Premixed is supplied as 100 mL or 250 mL of 0.9% sodium chloride containing 50 mcg/mL tirofiban. It is supplied in INTRAVIA³ containers (PL 2408 plastic). To open the INTRAVIA container, first tear off its foil overpouch. The plastic may be somewhat opaque because of moisture absorption during sterilization; the opacity will diminish gradually. Check for leaks by squeezing the inner bag firmly; if any leaks are found, the sterility is suspect and the solution should be discarded. Do not use unless the solution is clear and the seal is intact. Suspend the container from its eyelet support, remove the plastic protector from the outlet port, and attach a conventional administration set.
AGGRASTAT may be administered in the same intravenous line as atropine sulfate, dobutamine, dopamine, epinephrine HCl, famotidine injection, furosemide, lidocaine, midazolam HCl, morphine sulfate, nitroglycerin, potassium chloride, and propranolol HCl. AGGRASTAT should not be administered in the same intravenous line as diazepam.
In most patients, AGGRASTAT should be administered intravenously, at an initial rate of 0.4 mcg/kg/min for 30 minutes and then continued at 0.1 mcg/kg/min.
Patients with severe renal insufficiency (creatinine clearance <30 mL/min) should receive half the usual rate of infusion (see PRECAUTIONS, Severe Renal Insufficiency and CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations, Renal Insufficiency).The table below is provided as a guide to dosage adjustment by weight.
|Patient Weight (kg)||Most Patients||Severe Renal Impairment|
|30 Min Loading Infusion Rate (mL/hr)||Maintenance Infusion Rate (mL/hr)||30 Min Loading Infusion Rate (mL/hr)||Maintenance Infusion Rate (mL/hr)|
No dosage adjustment is recommended for elderly or female patients (see PRECAUTIONS, Geriatric Use). In PRISM-PLUS, AGGRASTAT was administered in combination with heparin for 48 to 108 hours. The infusion should be continued through angiography and for 12 to 24 hours after angioplasty or atherectomy.